| 1.96 -0.05 (-2.49%) | 04-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.29  |
1-year : | 5.75 |
| Resists | First : | 3.68 |
Second : | 4.92 |
| Pivot price | 1.93 |
|||
| Supports | First : | 1.65 | Second : | 1.38 |
| MAs | MA(5) : | 1.91  |
MA(20) : | 2.01 |
| MA(100) : | 2.69 |
MA(250) : | 4.01 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 51.7 |
D(3) : | 41.1 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 17.39 | Low : | 0.97 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CDIO ] has closed below upper band by 43.8%. Bollinger Bands are 84.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.07 - 2.08 | 2.08 - 2.08 |
| Low: | 1.9 - 1.91 | 1.91 - 1.92 |
| Close: | 1.94 - 1.96 | 1.96 - 1.97 |
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Fri, 10 Apr 2026
CDIO Should I Buy - Intellectia AI
Wed, 08 Apr 2026
IBN Initiates Coverage of Cardio Diagnostics Holdings Inc. - GlobeNewswire
Thu, 02 Apr 2026
[Form 4] Cardio Diagnostics Holdings, Inc. Insider Trading Activity - Stock Titan
Wed, 01 Apr 2026
Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’ - The Globe and Mail
Wed, 01 Apr 2026
Cardio Diagnostics Holdings (CDIO) Is 'One to Watch' - Yahoo Finance
Sun, 22 Mar 2026
If You Invested $1,000 in Cardio Diagnostics Holdings Inc (CDIO) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.83e+006 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 123 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.09e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -41 % |
| Return on Assets (ttm) | 159.5 % |
| Return on Equity (ttm) | -44.1 % |
| Qtrly Rev. Growth | 14820 % |
| Gross Profit (p.s.) | -9.51 |
| Sales Per Share | -35.26 |
| EBITDA (p.s.) | 6645.73 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 1.14 |
| Dividend | 0 |
| Forward Dividend | 160540 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|